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Introduction 
 
 
 
 
 
 
 
 
 
 
 
 Irritable bowel syndrome (IBS) is defined as “a functional bowel disorder in which 
abdominal pain or discomfort is associated with defecation or a change in bowel habit, and 
with features of disordered defecation”1. IBS is a relapsing functional bowel disorder which 
is diagnosed based on criteria including symptoms in those without any detectable organic 
causes. It is the most common gastrointestinal disorder diagnosed and accounts for around 30 
percent of all referrals to gastroenterologists2. Previously diagnosis of IBS was made after 
exclusion of all organic causes. After the introduction of new and more precise clinical 
criteria, i.e. “Rome criteria”, it has allowed to make a diagnosis of IBS on the basis of 
symptoms alone without extensive evaluation3. 
 
 In 1978 Manning et al formulated a group of symptoms to diagnose IBS. These were called 
as Manning criteria for diagnosis of IBS4.  Soon various definitions for IBS were introduced. 
Hence to standardize the definition of IBS especially for research, an international working 
group published a consensus definition in 1992 which is called as the Rome criteria, last 
revision of which was done in 20051. Of these most commonly used criteria in clinical 
practice and various studies are Rome II and III. 
 
IBS is considered to be the most common of all gastrointestinal disorders which has variable 
prevalence of 5-25 % worldwide.   In a prospective, multi-centre study by Ghoshal UC et al, 
data was collected from 2785 patients who presented with chronic lower gastrointestinal 
symptoms and  concluded that symptoms suggestive of IBS was present in 4.2% in 
community subjects 5.In another study which included 2,549 subjects from an urban 
community from Western part of India, Shah et al reported the prevalence of IBS as 7.5% 
using Manning criteria6. The prevalence of IBS from population-based studies in North 
America estimated is around 10 to 15 percent6,7. A community based study from Europe 
showed a prevalence of 11.5 %, however, the prevalence was variable among different 
countries8. 
 
IBS can affect both males and females including elderly. However, IBS is more common in 
younger population. In a systematic review from North America, there was female 
predominance with overall ratio of female: male 2:1 9. Studies from India have been varying, 
but majority have shown male predominance 5,6. Patients with IBS present with various 
symptoms which may be gastrointestinal or extra intestinal complaints. However, the 
symptom of prolonged pain abdomen with altered bowel habits is the primary characteristic 
of IBS but is non specific.  Abdominal pain is usually mild and has waxing and waning 
character. There is wide variation in location and intensity of pain in patients with IBS 
1,10. Patients present with altered bowel habits, which range from diarrhoea, constipation, 
alternating diarrhoea and constipation, or normal bowel habits alternating with either 
diarrhoea and/or constipation. Depending on predominant symptoms IBS is sub classified 
into diarrhoea predominant (IBS-D), constipation predominant (IBS-C) and Mixed or 
Intermediate (IBS –I). 
 
 Despite high prevalence in general population the path physiology of IBS remains uncertain. 
A number of mechanisms have been implicated in the pathogenesis of IBS, which include 
altered GI motility, visceral hypersensitivity, altered gut flora,  low-grade inflammation, 
stress among the others11,12. Small bowel and colonic transit time has been documented to be 
delayed in IBS-C and accelerated in IBS-D8. It is shown that IBS develops in about 7% to 
30% of those subjects who have recovered from an episode of bacterial enteritis 13. It has 
been postulated that the colonic flora could be abnormal in some of IBS subjects, which 
results in increased colonic fermentation, excess production of gas, and development of 
symptoms associated with the disease14. One of the associations of IBS which has been 
proposed is with small intestinal bacterial overgrowth (SIBO). 
 
SIBO is a condition which is characterised by increased number of bacteria (>105 bacteria/ml 
in jejunal fluid), in small intestine which predominantly include species commonly present in 
colon.  Whether or not SIBO contributes to some of the symptoms in IBS such as gas and 
bloating is an area of active investigation. The gold standard used for the diagnosis of SIBO 
includes demonstration of more than 105 colony forming units(CFU)bacteria/ml of fluid from 
jejunal aspirate. Non-invasive breath tests are commonly used to diagnose SIBO in clinical 
practice. These tests are based on detection of gases like hydrogen or methane, which are 
produced by bacteria in intestines after metabolism of carbohydrates like glucose or lactulose.  
 
In a study by Pimentel et al. abnormal breath test results suggesting SIBO was found in 
78%15. In another study by the same group the incidence of an abnormal lactulose breath test 
in subjects with IBS (as per Rome II) was 84% vs. 20% in the control of subjects 16. The 
normalization of the lactulose BT after the use of antibiotics along with a significant 
reduction of IBS symptoms was also noted in the same study. 
 
A study by Rana SV et al. showed that the prevalence of SIBO in IBS patients from North 
India was 11.1% 17. In a study by Ghoshal UCet al  the noted prevalence of SIBO was 8.5% 
18 and in a study by Sachdeva S et al it was 23.7%19. 
 
In addition to constipation, diarrhoea, or pain many of the IBS patients also present with a 
significant bloating component to their presentation. Recent data suggest that abnormalities in 
gas production and its transit through the small intestine could explain these symptoms20. 
Whether SIBO contributes to some of the distressing symptoms such as gas and bloating in 
IBS remains to be established.  
 
The association between SIBO and IBS continues to be controversial with prevalence in 
different parts of the world being apparently quite different. There is a paucity of studies from 
south India. Hence the present study was planned to find out the prevalence of SIBO in IBS 
patients using glucose hydrogen breath test (GHBT). The study also aimed to evaluate 
symptom correlation of SIBO in these patients with abnormal GHBT. The patients were also 
planned to undergo lactulose hydrogen breath test (LHBT) to estimate orocecal transit time 
(OCTT) and to analyse if it was different in different subgroups of IBS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
AIMS 
 
 
 
 
 
 
 
 
 
The primary objective of the present study was to study prevalence of abnormal glucose 
hydrogen breath test, as a marker for Small Intestinal Bacterial Overgrowth (SIBO), in 
patients with Irritable Bowel Syndrome (IBS) and to correlate with the symptoms.  
 
The study also aimed to find out the orocecal transit time in these patients using the lactulose 
hydrogen breath test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Review of Literature 
 
 
 
 
 
 
 
 
 
Definition 
Irritable bowel syndrome (IBS) is defined as “a functional bowel disease in which abdominal 
discomfort or pain that is associated with a change in bowel habit. ”1 . 
 
A diagnosis of IBS is based on symptoms which are consistent with the condition, and after 
exclusion of other conditions which present with similar clinical presentation in a cost-
effective manner. These conditions include any other organic or functional disorders8. This 
strategy was recommended by 2009 American Gastroenterology Association (AGA) practice 
guidelines.  
 
Diagnostic Criteria for IBS 
There have been multiple diagnostic criteria which have been described previously. 
 
 In 1978 Manning et al formulated a symptom complex suggestive of IBS, which are referred 
to as Manning criteria4. By using these criteria, studies which were done showed that this was 
more specific in identifying the patients with IBS but was less sensitive. These criteria were 
of greater diagnostic value in women as compared to men 21. 
Manning criteria for IBS are as follows 
· Abdominal pain eased after bowel movement 
· Looser stools at onset of abdominal pain 
· More frequent bowel movements at onset of abdominal pain 
· Abdominal distension 
· Mucus per rectum 
· Sensation of incomplete emptying 
 
The Kruis scoring system22 was the other diagnostic criteria which were used for the 
diagnosis of IBS. The criteria were based on the history of the patients, assessment by the 
physician including physical examination and simple blood tests. As per the criteria a 
diagnosis of IBS was not considered if there were abnormal findings on physical 
examination, low haemoglobin ( <14 g/dl in males: <12 g/dl in females), high total leucocyte 
count (>10,000/mm3) or raised ESR (>20 mm at 2 hours). It had modest diagnostic utility. 
 
As there were multiple criteria were being used for diagnosis of IBS, Rome criteria were 
established in order to standardise the diagnosis of IBS especially for clinical research 
purposes in 1992. Till date there are Rome I, II and III criteria are described with latest 
revision being in 2005. The sensitivity and specificity of the Rome I criteria have been 
reported to be 71% and 85%, respectively23.  The main components of Rome II and III 
criteria are very similar but adequate validation of Rome III has not been done. 
 
The Rome II diagnostic criteria24 for IBS:  
These are already described in detail under the heading of methods in the earlier section. 
Depending on the predominant symptom IBS can be subdivided into three groups which 
include IBS –D, IBS-C and IBS-I. 
 
The Rome III diagnostic criteria1 for IBS:  
Recurrent abdominal pain or discomfort at least three days/month in the last three months 
associated with two or more of the following: 
    · Improvement with defecation 
    · Onset associated with a change in frequency of stool 
   
 · Onset associated with a change in form (appearance) of stool 
 
Based on Bristol stool form, IBS patients are sub classified in to 4 types which is presented in 
table no 1 1. 
Table no. 1: IBS subtypes as per Rome III  
1 IBS - C hard stools ≥ 25%*  and watery stools < 25 % 
2 IBS - D watery stools ≥ 25 % and hard stools < 5% 
3 IBS - M watery stools ≥ 25 %  and  hard stools ≥ 25% 
4 IBS - U who do not fit into other subtypes 
 C- constipation, D – diarrhoea, M – Mixed, U – unsubtyped, 
* % based on number of bowel movements 
 
 
Epidemiology of IBS 
IBS is considered as the most common functional bowel disease worldwide. There is a 
considerable variation in epidemiology of IBS especially in studies from India and west. 
 
In a study by Shah et al which was published in 2001 reported the prevalence of IBS as 7.6%. 
The study was a community based one which used Manning criteria for diagnosis of IBS. In 
this study total of 2549 apparently  healthy adults (mean age 37.2 years; 1441 men) were 
interviewed using a detailed symptom questionnaire6.  
 
A prospective multicentre study was conducted by Indian society of Gastroenterology task 
force and was published in 2008. In this study data were collected from 2785 subjects who 
presented with chronic lower GI symptoms in 30 centres and 4500 asymptomatic community 
subjects, using separate questionnaires. The study reported that symptoms complex 
suggestive of IBS was present in 4.2% in community population. The study also showed 
slight male predominance in prevalence of IBS with 4.3% in males as compared to 4% in 
females5. 
 
A prospective study was done by Makharia et al which was published in 2011. The study 
included 4767 subjects from rural north India who were interviewed with questionnaire of 
IBS. Using Rome III criteria, 191 patients were diagnosed with IBS. The prevalence of IBS 
in the study was 4%. In the study IBS-M was the most common presentation with 42.4%. 
IBS-D, IBS-U and IBS-C were diagnosed in 37.7%, 13.6% and 6.3% respectively. In this 
study, mean age was 34.6 (± 10.8) years. Females had a higher prevalence of IBS with 4.8% 
as compared to 3.2% in males 25.  
 
The prevalence of IBS from population-based studies in North America estimated is 
approximately 10 to 15 percent. Male to female ratio was 1:2 7,8. A community-based study 
from Europe showed a prevalence of 11.5 %, however, it varied widely among countries9.  
 
As can be seen from the data presented above, it can be noted that the prevalence of IBS in 
India is much lower than that reported from the West. The prevalence of IBS in India is also 
much lesser as compared to other population based studies from other countries from Asia 
like China (11.5% by Manning criteria)26,  Bangladesh (8.5% by Rome II criteria)27, Pakistan 
(14% by Rome II criteria)28.  
 
The incidence of irritable bowel syndrome is uncertain. A study from Olmsted County in 
United States of America by Locke III GR et al reported that the incidence of  IBS in was 
0.2% per year based on clinical diagnosis29. 
 
Pathogenesis of IBS 
Despite high prevalence exact aetiology and pathogenesis of IBS remains unknown. Multiple 
mechanisms have been described in the etiopathogenesis of IBS, which include altered 
intestinal motility, low-grade inflammation, genetic factors, dietary factors, abnormal 
expulsion of gas, visceral hypersensitivity, and stress among the various others. Genetic 
factors are postulated to alter the processing of the inflammatory and immune responses 
locally and GI signals centrally which can predispose to IBS. Hence it may be reasonable  to 
postulate that “multiple hits” rather than a single mechanism is required to manifest IBS 2,11. 
Various factors are explained in brief in the following section.  
Altered colonic and small bowel motility 
Symptom of diarrhoea in functional bowel diseases like IBS can be explained by multiple 
mechanisms like increased high-amplitude propagated contractions (HAPCs), increased 
motor activity in recto sigmoid region soon after meal which is called gastro colic response, 
 
Fig no.2: A conceptual model of IBS which depicts relationship between various factors 2 
 
 or rectal hypersensitivity. Constipation in these subjects could be explained by increased non 
propulsive contractions, reduced number of HAPCs, or impaired rectal sensation30. Previous 
studies have shown that small intestine and colonic transit is delayed in IBS-C and 
accelerated in IBS-D 31. Increased HAPCs can also explain abdominal pain. It has also been 
demonstrated in prior studies that colonic transit is accelerated by stress or instillation of bile 
acid like deoxycholic acid, but such alteration in transit is not specific for IBS subjects8. 
 
Visceral hypersensitivity 
In a study by Ritchie J et al, balloon in rectum was inflated at various volumes in IBS 
patients and controls. It was shown in the study that balloon distension induced pain at lower 
volumes in patients with IBS which suggests that hypersensitivity of rectum or colon may be 
involved in pathogenesis32. It is not a universal phenomenon but was seen in 60% of patients 
of IBS, hence can’t explain the symptom in all patients. It has been demonstrated that patients 
of functional bowel disease are more likely to appreciate intestinal contractions or gas as 
compared to others after meal or in association with stress. Various  neurotransmitters  are 
known to be involved in visceral hypersensitivity, among which serotonin is most 
important33. 
 
Abnormal dynamics of gas  
It is demonstrated in studies that abdomen normally swells during the day, which attains its 
peak in the evening and decreases on lying down during abdominal girth monitoring of 
ambulatory subjects. One of the mechanisms which has been proposed in pathogenesis of  
IBS is that, such a phenomenon may often be exaggerated in subset IBS subjects, which may 
explain bloating 34. Following infusion of gas in small bowel, it was noted that IBS subjects 
retained more gas than controls in a study. When asked not to pass gas voluntarily after 
infusion of gas, IBS subjects felt more discomfort as compared to healthy controls 35. 
 
Local inflammation 
The human gastrointestinal tract (GIT) is in a state of chronic inflammation normally, as a 
result of constant interaction between normal enteric bacteria and the mucosal immune 
system. It has been demonstrated that inflammatory cells, including mast cells and T 
lymphocytes are present in higher numbers in the mucosa of a subgroup of IBS patients, 
which may suggest that an ongoing low-grade inflammation may be present in these patients. 
Nearly 7% to 30% of patients after recovering from a documented episode of enteritis caused 
by bacteria, have been demonstrated to develop IBS subsequently. This is described as post- 
infectious IBS. The risk of this increases, if the episode of bacterial enteritis is longer than 
three weeks or it is caused by the organisms which are toxigenic36 There is evidence of  
increased production of  serotonin, arachidonic acid metabolites and adenosine in areas of 
colonic inflammation in IBS. There is also increase in various chronic inflammatory and  
enteroendocrine cells. It has also been demonstrated that increased intestinal permeability by 
using the lactulose-mannitol test in patients with post-infectious IBS37. 
 
Role of food 
Many patients with IBS complain about worsening of symptoms after consumption of certain 
foods which include wheat, egg, dairy products, and onions among others. One of the 
common associations with IBS is intolerance after consumption foods containing wheat. In a 
study involving IBS-D patients who were positive for HLA DQ2 symptoms in 70% of 
patients as compare to 20% who were negative , after a  6 month gluten-free diet 38.  
 
FODMAP is an acronym for fermentable oligosaccharides, disaccharides, monosaccharides 
and polyols. These are dietary constituents which are poorly absorbed, and produce short-
chain fatty acids in the small bowel. These short chain fatty acids may induce symptoms of 
IBS through their effects on colonic motility and secretion39. It is also shown in various 
studies that the symptoms of IBS improve after avoidance of these ingradients in the diet. 
Patients of lactose intolerance may also have symptoms which overlap with those with IBS. 
In a study by Gupta D et al from north India demonstrated that the frequency of lactose 
intolerance was high among IBS patients (n=89, as per IBS II) and comparable with control 
subjects (n=53), was 72% and 60% respectively which was statistically insignificant. The 
study also concluded that there was poor sensitivity of self-reported intolerance to milk in 
detecting lactose intolerance40. Malabsorption of fructose or sorbitol has been shown to 
contribute to few symptoms of a subset of IBS subjects; but this mechanism is unlikely to be 
more common given a high prevalence of IBS41. 
 
Altered central regulation  
Normally afferent signals from gastrointestinal tract reach thalamus via brainstem but such 
signals are consciously perceived only rarely. Alteration and modulation of these afferent 
signals can occur at various levels which include enteric, spinal, and central levels. Studies 
which are based on functional brain imaging that detect changes in blood flow, have 
suggested that after visceral stimuli, responses in brain are varied in subjects of IBS as 
compared to healthy controls. In a study with IBS subjects, after delivered or anticipated 
rectal distension, there was higher activation of the mid-cingular cortex. These observations 
suggest why stress or anxiety can increase the perception of visceral pain and  relaxation can 
decrease perception of pain  in subjects with IBS42. 
 
Psychological factors 
As many as 40 to 94% of patients with IBS have associated anxiety, depression and 
somatisation, which are the most common psychiatric conditions associated with IBS 43. A 
childhood history of abuse is often noted in patients with IBS than in those without which 
may be emotional or physical including sexual.  Altered central brain modulation in response 
to pain can explain in some of these patients. Subjects with IBS more commonly report a 
higher lifetime and daily  events with stress than healthy people or those having organic 
diseases 8. 
Genetic factors 
Hereditary component in IBS is increasingly being recognised but evidence is limited.  Twin 
studies have shown higher concordance in monozygotic as compared dizygotic twins in 
patients with IBS. Various candidate genes have been postulated to be associated with IBS, 
but further studies and investigations are required before their functional significance is 
understood44. 
 
There has been varied association between SIBO and IBS which is reviewed in the following 
section. 
 
Small intestinal bacterial overgrowth (SIBO)  
SIBO is defined as a disorder where there are increased numbers of bacteria, which are 
mainly colonic type (>105 bacteria/ml in jejunal fluid), present in the lumen of the small 
intestine45.  In SIBO multiple organisms are present in varying numbers. Common species 
include Streptococci, Bacteroides, Escherichia, and Lactobacillus46. The upper small bowel 
contains relatively low bacterial counts because of increased acid content and normal 
peristalsis as compared to distal intestine. Normally upper small bowel shows bacterial count 
lower than 1000 per ml of aspirate.    
 
The aetiology and proposed pathogenesis is presented in table no 2. IBS is one of the 
proposed causes of SIBO but the exact pathophysiology is not known. 
 
Table no. 3: Pathophysiology and conditions associated with SIBO 
Pathophysiology Causes  
Abnormal anatomy Blind loop syndrome – post surgical 
 
Jejunal diverticulosis 
 
Stricture of small bowel 
 
Gastrocolic or Enterocolic fistula 
Altered motility Diabetes mellitus 
 
Connective tissue diseases like 
Scleroderma 
 
Idiopathic 
 
Reduced gatric acid  Post vagotomy state 
 
Drugs – Ex: proton pump inhibitors 
 
Atrophic gastritis 
Multiple mechanisms – known or unknown IBS 
 
Chronic pancreatitis 
 
Chronic liver disease 
 
Chronic kidney disease 
 
 
The gold standard method used for the diagnosis of SIBO involves demonstration of >105 
colony forming units (CFU) of bacteria/ml of jejunal fluid. Unfortunately, such aspiration is 
invasive and time-consuming. It has been argued that this method may not detect bacterial 
overgrowth if it involves only distal small intestine. In a study by Corazza and colleagues, 
when intestinal fluid was assessed by collection at two different sites in jejunum, bacterial 
counts showed a good correlation 47. Problems commonly encountered during jejunal aspirate 
are (a) contamination with oral organisms during aspiration (b) technical difficulty and, (c) 
availability of media required for transport and culture of aspirate. 
In order to overcome these problems, various non invasive tests have been developed for 
diagnosing SIBO which include the breath tests. Hydrogen or methane gas is produced when 
glucose or lactulose is metabolised by the bacteria in intestine. Majority of it is consumed by 
bacteria and only a small fraction of this gas is excreted by the various routes. The hydrogen 
which is excreted via lungs is detected in the breath which forms the basis of these tests.  
These HBTs are based on basic principle that other than the metabolism of undigested 
carbohydrates there is no other source of hydrogen gas in human body 48. The principle of 
breath test is shown in figure no. 2. Hydrogen or methane detected in breath are expressed in 
parts per million (ppm).  
 
There are several potential problems which are associated with conduct of breath tests. 
Approximately 15% of the healthy subjects are considered as predominant methane 
producers. These indivisual’s intestines are colonized with Methanobrevibacter smithii. In 
these persons hydrogen gas produced reacts biochemically with carbon dioxide to produce 
methane. This leads to less hydrogen being produced in these persons as compared to others 
and hence hydrogen may not be detected in breath tests and predominantly methane is 
detected.  Altered intestinal motility may affect the accuracy of these tests. The result of 
breath tests, especially the baseline value, will also be affected by recent consumption  of diet 
which has high content of non digestible carbohydrates by the persons undergoing these tests, 
smoking and physical exercise prior to test 49. 
 
For detection of SIBO, glucose HBT was shown to have sensitivity varying from 27% to 52% 
and specificity of 30% to 83% in the previous studies. It has been shown that with altered 
intestinal motility results of LHBT are difficult to interpret. This leads to varying sensitivity 
and specificity for LHBT 47. 
 
Fig no. 3: Figure which depicts principle of HBTs50
 
 
IBS and SIBO 
Many patients with SIBO fulfil the diagnostic criteria for IBS because symptoms of both of 
these conditions overlap. Bacterial flora in small intestine of a subset of IBS subjects could be 
abnormal which results in increased fermentation leading to excessive gas 14. It has been 
postulated that this leads to symptom of bloating. Based on these observations, there have 
been multiple studies on their association and the clinical trials of improvement in symptoms 
with use of antibiotics or probiotics.  
In a study of 202 patients, who met Rome I criteria for IBS, by Pimentel et al using lactulose 
HBT, SIBO was found in 157 (78%) of patients. Out of these 202 patients 76.7% were 
females and mean age was 41.9 (± 15.2) years. LHBT was done using 10 g of lactulose in the 
study and was taken as positive if hydrogen level was  more than 20 ppm. In those who had 
abnormal HBT, 10 day course of antibiotics were administered as per discretion of physician. 
The study also showed that use of antibiotic therapy reduced hydrogen production and 
improved  symptoms 15.  
 
In another study by the same group LHBT was 84% (93/111) in IBS patients as against 20% 
(3/15) in healthy people. IBS was diagnosed using Rome I criteria in the study. This study 
was a randomised control trial with 111 IBS subjects of which 55 were treated with 
neomycin, 56 with placebo. The study showed that there was significant improvement in 
compostite score which was used in study and normalization of bowel habits in those treated 
with  neomycin than those with placebo 16. 
 
In a study from Italy, a total of 65 IBS subjects (as per Rome II) and 102 healthy subjects 
were enrolled. Glucose HBT was done with 50 g and positive HBT taken as >10 ppm above 
baseline. Positivity GHBT was noted in 31% of IBS and 4% in the control population. This 
was statistically significant 51. 
 
A study by Rana SV et al. from PGI, Chandigarh showed that the prevalence of SIBO was 
11.1%  in IBS subjects. The study included 225 patients with IBS (as per Rome II criteria) 
and 100 healthy people as control population.  Out of these patients with IBS, 71.1% were 
males. Mean age for male patients was 43.5 (20-65) yrs and 48.7 (16-60) yrs for females. 
GHBT was done with 50 g and positive HBT was taken when hydrogen in breath exceeded 
12 ppm above baseline. This study concluded that SIBO was more common in IBS patients 
(11.1%) as compared to controls (1%), which is lower than the reported prevalence 
elsewhere17. 
 
In a study by Ghoshal UC prevalence of SIBO in IBS was 8.5%. In this study 129 patients of 
IBS as per Manning's criteria, 73 with chronic non specific diarrhoea, CNSD (defined as 
diarrhoea for ≥ 4 weeks, with atleast 2out of 3 normal test results of urine xylose, syool fat 
and D2 biopsy) and 51 control subjects were included.  They were evaluated for SIBO using 
glucose HBT. Majority of IBS patients were males (83.7%) and age was 36.6 (± 11.4) yrs. 
GHBT was done with 100 g and positive HBT was diahnosed when hydrogen in breath 
exceeded 12 ppm above baseline.  Of total of 129 patients with IBS, IBS – I was diagnosed in 
122 and IBS –C in 7, 20 patients with IBS-D were included in CNSD group. In the study 
none of patients with IBS-C had SIBO. There was no significant difference in prevalence of 
SIBO in patients with IBS-D as compared to other subjects with CNSD. This study 
demonstrated that SIBO using GHBT was commoner in CNSD (21.9%) than in IBS (8.5%) 
or healthy control subjects (2%) 18. 
 
In a study by Sachdeva et al 59 of IBS patients (as per Rome III) and 37 controls were 
included. Among patients with IBS, 27 were IBS-D subtype, 11 were IBS-C & 21 were M-
IBS- M. Median age was 34 (18-74) yrs in these IBS subjects and majority were males 
(69.5%). GHBT was done with 100 g and abnormal HBT was considered when hydrogen in 
breath exceeded 12 ppm above baseline.   SIBO (using GHBT) was statistically more 
common in IBS subjects (23.7%) as compared to healthy controls (2.7%). The study also 
concluded that IBS-D subtype, female sex & symptom of  bloating as probable predictors of 
SIBO in those diagnosed with IBS19. 
 
A Swedish study by Posserud et al included 161 IBS patients (who fulfilled  Rome II criteria) 
and 42 healthy controls. The mean age of IBS subjects was 38 (19– 68)yrs majority were 
females (120). Among them 49 patients belonged to IBS- D category, 37 to IBS-C and 76 to 
IBS-I. A subset of patients also underwent glucose and lactulose HBT. Using jejunal cultures 
to diagnose SIBO (>105 /ml), the study showed that frequency of SIBO was same in both IBS 
patients and healthy controls at 4%.The authors refuted any strong association of SIBO and 
IBS using gold standard of jejunal aspirate and HBTs 52. 
 
In a meta-analysis by Ford AC, published in 2009, included 12 studies with 1921 r IBS 
subjects. In this study pooled prevalence of a positive LHBT was 54% (95% CI, 32%–76%) 
and GHBT was 31% (95% CI, 14%–50%). This meta-analysis showed the pooled odds ratio 
SIBO in comparison to control population was 3.45 (95% CI, 0.9–12.7) or 4.7 (95% CI, 1.7–
12.95), based on the criteria used for the study. The authors concluded that the role of testing 
for SIBO in individuals with IBS remains unclear53. 
 
In a meta-analysis by Shah et al published in 2010 included 11 studies (1,076 patients with 
IBS and 509 healthy controls). Abnormal HBTs were more common in IBS patients as 
compared to healthy controls (OR = 4.46, 95% CI = 1.69– 11.80).  This association became 
more apparent when better designed age- and sex-matched studies were taken (OR = 9.64).. 
But the studies were heterogeneity in criteria used for selection, substrate used for HBT and 
cut off used for positive HBT 54. 
 
A number of studies were done to assess the role of antibiotics in treatment of SIBO in 
patients of IBS. Pimentel M et al studied 87 patients with IBS (using Rome I), and were 
administered 400 mg of rifaximin or placebo thrice a day for a period of 10 days. At the end 
of 10 week follow up period, comparison of the global improvement scores of rifaximin vs 
placebo groups demonstrated an average increase of 36.4% vs 21%, respectively55. 
 
Two studies were designed by TARGET group which were phase 3 double blind RCTs which 
were called TARGET 1 and 2. In this study IBS subjects without constipation were divided 
into two groups randomly, one received rifaximin (at 550 mg thrice daily) or placebo for two 
weeks.  After combining both the studies, rifaximin arm had significant relief of global 
symptoms at 4 weeks as compared to placebo arm (40.7% vs. 31.7%, P<0.001). Both the 
studies individually also had statistically significant difference between the two groups56.  
 
A study by Meyrat P et al  included 106 of 150 IBS patients diagnosed with SIBO using 
LHBT. They were treated with rifaximin (800mg/day) for a total duration of two weeks. All 
the patients were assessed using a questionnaire of symptom severity on a Likert scale at the 
onset,  4 and 10 wks after the treatment. This study showed a significant improvement in IBS 
symptoms at the end of three months.  86% of those undergoing repeat LHBT at 4 weeks had 
a negative test 57. 
 
Factors that predict SIBO in IBS 
Few studies in the past have evaluated the factors that predict SIBO in IBS patients. In a 
study by Reddymasu et al, which was a retrospective study, included  IBS patients (as per 
Rome II criteria) and underwent HBT using 50 g of glucose. Bloating and flatulence were 
predominant symptoms in all 98 patients of IBS.  Among them 52% had IBS-C, 39% IBS-D, 
and 9% had IBS-I. SIBO was diagnosed in 35 (36%) patients as per abnormal GHBT. The 
study concluded that older age (>55 yr) and female gender could be used as predictors of 
SIBO in IBS58. The study also showed that in subgroup of IBS subjects with bloating and 
flatulence as the predominant symptoms, SIBO was present in sizeable patients.  
 
In a study by Sachdeva et al concluded that IBS-D subgroup, female sex & bloating as 
probable predictor factors of SIBO in those with IBS19.  A study by Law et al concluded that 
hydrogen production was unaffected by PPI use on LHBT in IBS subjects (as per Rome I) 59.  
 
Orocecal transit time (OCTT) 
The importance of GI motility in the pathogenesis of gut symptoms including functional 
bowel diseases like IBS is well known. Various methods have been developed to assess small 
bowel transit time clinically. OCTT is a marker of gastric and small bowel motility time 
together. The techniques that are available to measure OCTT include the breath hydrogen test 
and gamma scintigraphy.  Breath tests measure H2 or CO2 (which is labelled with 13C or 14C), 
which are produced when test meal undergoes metabolism by bacteria after reaching colon 
and these gases are produced and are exhaled. Scintigraphic tests actually measure time taken 
by the meal with radiolabelled marker to reach cecum. 
 A typical liquid meal which is used to measure OCTT contains 10 g of lactulose in 100 mL of 
water.  Usually a solid meal to measure OCTT contains baked beans as which has stachyose 
and raffinose which are not absorbed in small bowel. Lactulose is a disaccharide  which is not 
not absorbed in small bowel and gets fermented after reaching the colon by bacteria present 
there. It has been shown in previous studies that OCTT in healthy subjects is between 40 and 
170 min for lactulose meal60 and between 192 - 232 min for a solid meal61. There are multiple 
factors which can alter OCTT. 
 
Studies on OCTT in IBS 
Cann PA et al in1983, published a study that included 61 patients (46 females ; mean age 36 
yrs) with symptoms suggestive of IBS and 53 controls. The study patients had  three sub 
groups - constipation predominant (23), diarrhoea predominant (21) and abdominal 
pain/distension predominant group (17). OCTT was calculated by with solid test meal and 
breath hydrogen analysis. The study concluded that OCTTs were significantly shorter in 
subgroup of subjects with diarrhoea (3.3±0.3 vs 4.2±0.2 h; p=001) and prolonged  in patients 
whose with constipation (5.4±0.3 vs 4.2±0.2 h; p<001) or pain and distension (5.4±0.4 vs 
4.2±0.2 h; p<001) in comparison with controls62. 
 
In a study by Sadik R et al included 96 IBS and 83 controls. Among those with IBS 34 had 
IBS-D, 16 had IBS-C and 46 IBS-I (or A).  Gastric emptying, small intestine and colonic 
transits were measured in all of them. At least one transit abnormality was found 51%. In 
females, small intestine and colonic transit was significantly slower in IBS-C in comparison 
to IBS-D63. 
 
In a study by Derek Yu et al orocecal scintigraphy and LHBT both were done in 40 IBS 
patients (as per Rome II criteria) to assess if the rise in H2 is due to the test meal reaching the 
cecum. Subjects ingested a test meal which contained 99mTc and 10 g of lactulose. They all 
underwent LHBT and scintigrapgy at the same time. The OCTT based on scintigraphic 
scanning ranged from 10 to 220 min. There was a very strong correlation between the timing 
of cecal radioactivity positivity and rise in H2 breath (p = 0.0025).The mean OCTT was 
prolonged in IBS- as compared to IBS-D almost 2.2 times (p =0.0023). The authors of the 
study concluded that an abnormal rise in H2 measured in the LHBT can be explained by 
variations in OCTT and not support the diagnosis of SIBO 64. 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Material and Methods 
 
 
 
 
 
Study design  
This was a prospective observational study performed in the Christian Medical College, 
Vellore 
Inclusion criteria 
· Adults aged 18 years or more who fulfilled Rome II criteria for diagnosis of Irritable 
Bowel Syndrome (IBS) 
 
Exclusion criteria 
· Not consenting to participate  
· Recent hospitalization and/or antibiotic use in preceding 2 weeks 
· Lactulose use in past one week 
· Colonoscopy in past one week 
· Prior major gastrointestinal surgery  
· History of  diabetes mellitus or other systemic illness 
· Treatment history with drugs  which are known to alter the gastrointestinal motility 
(such as anticholinergics, opiates, antidepressants, prokinetics,) or probiotics 
 
 
Study setting and Population 
The study was conducted in the Department of Medical Gastroenterology in CMC Hospital, 
Vellore from August 2012 to December 2013.Consecutive patients fulfilling inclusion and 
exclusion criteria were recruited from outpatient department (OPD) of the Gastroenterology 
clinic during the study period. The purpose of the study and methodology was explained to 
these patients in detail in their own colloquial language and informed written consent was 
taken.  The patients were scheduled to undergo glucose and lactulose hydrogen breath tests 
(HBTs) on two consecutive days. They were explained in detail about the procedure of the 
test and other instructions including diet that needed to be followed prior to test.  Hydrogen 
breath tests were done free of cost as a part of the study protocol. No additional clinical 
laboratory tests were performed for the study other than those dictated for clinical care. Study 
plan is presented in the following flow diagram (Figure 1). 
Consecutive IBS 
patients from OPD
Glucose and Lactulose
Hydrogen BT
Gluose HBT Lactulose HBT
Positive Negative OCTT#
calculable
OCTT#
incalculable 
Figure 1 : Study Plan              
# - OCTT- Oroecal Transit Time
 
Informed Consent Process  
Those patients who met the criteria were explained about the background and purpose of the 
study in detail and they were invited to participate. If the patients were willing to participate, 
then written consent was obtained from the patient as per consent form appended. 
 
 
Ethics Committee review  
The Human Ethics Committee of CMC Vellore reviewed and approved the proposal and 
consent forms. 
 
Study Monitoring  
The study was an investigator-initiated study conducted in Christian Medical College, 
Vellore. The candidate conducting this study personally ensured the entry criteria of the 
patient and collected the relevant clinical and laboratory details from the patient. Consecutive 
patients were enrolled, subject to consenting. 
 
Methods of the Study 
This study was conducted at Christian Medical College, Vellore, Tamilnadu, India. Relevant 
clinical and laboratory data were collected from the patients by the investigator in charge of 
the study, after obtaining the informed consent and ensuring entry criteria. 
 
The patients who consented for the study underwent glucose and lactulose HBTs on two 
consecutive days. The following instructions were given to the patients to be followed prior 
coming for breath test 
· To avoid non fermentable carbohydrate (pasta, breads, potato and fibre cereals) one 
day before the test 
 
· Take nothing by mouth overnight  (after 10 PM) 
 
·  Avoid candy and chewing gums at least an hour before the test. 
 
· Avoid smoking and physical exercise for two hrs prior to and during testing 
 
· To brush teeth on the morning  of the day prior coming for testing 
 
 
 
Glucose Hydrogen Breath Test (GHBT)  
Breath analysis of hydrogen was done using Bedfont Hydrogen Breath Analyser, UK. 
Hydrogen level was measured in parts per million (ppm). Methane was not analysed in the 
test.  Breath test was performed after overnight fast. Before the test, subjects were asked to 
rinse mouth with 1% chlorhexidine mouth wash to eliminate early hydrogen peak due to 
action of oral bacteria on test sugars. Patients gave a fasting breath for analysis of baseline 
hydrogen breath. This was be followed by oral intake of 70 gram of glucose dissolved in 1 
glass of water (200 ml). Hydrogen in the breath was measured in ppm every 20 minutes for 
over next 120 min (2 hours). If there was very early peak in the breath hydrogen (basal or at 
20 min), the whole test was repeated after mouth wash or postponed to next day.   
 
Lactulose Hydrogen Breath Test (LHBT) 
Subjects were asked to rinse mouth with 1% chlorhexidine mouth wash after an overnight 
fast. Patients gave a fasting breath for analysis of baseline breath hydrogen level. This was 
followed by oral intake 20 gram of lactulose in 1 glass of water (200 ml). Breath hydrogen 
was measured in ppm every 15 minutes over next 180 min (3 hours).  Analysis of hydrogen 
in breath was done using Bedfont Hydrogen Breath Analyser, UK. Methane was not analysed 
in the test. If there was very early peak in the breath hydrogen (< 30 min), whole test was 
repeated after mouth wash or postponed to next day.  
 
Sample size  
Sample size was calculated according to formula  
n = 4PQ/ d
2 
 
Where n = sample size, P is prevalence of the disease, Q =1-P and d is the precision  
From the previous studies, prevalence of IBS was noted to be 5-25% of the general 
population. For calculation of sample size a mean prevalence 15 % was taken. With precision 
of study as 5 and prevalence of 15%, sample size was calculated as 156 from the above 
formula. For probable dropouts another 20 % was added and final sample size was arrived at 
187.  
 
The patients were recruited from out patients department (OPD) of Gastroenterology, 
Christian Medical College, Vellore who fulfilled the entry criteria and consented for the 
study. The following criteria were used for the study. 
 
The Rome II diagnostic criteria for IBS 
At least 12 weeks or more, which need not be consecutive, in the preceding 12 months, of 
abdominal discomfort or pain that has two out of three features:  
(1) Relieved with defecation; and/or  
(2) Onset associated with a change in frequency of stool; and or  
(3) Onset associated with a change in form (appearance) of stool.  
The following symptoms cumulatively support the diagnosis of IBS  
- Abnormal stool frequency (for research purposes “abnormal” may be defined as greater 
than three bowel movements per day and less than three bowel movements per week);  
- Abnormal stool form (lumpy/hard or loose/watery stool);  
- Abnormal stool passage (straining, urgency, or feeling of incomplete evacuation);  
- Passage of mucus;  
- Bloating or feeling of abdominal distension.  
* In the absence of structural or metabolic abnormalities to explain the symptoms  
 
Patients with IBS are classified into three types using standard criteria as follows:  
(i) Diarrhoea predominant (IBS-D), >3 loose stools/d  
(ii) Constipation predominant (IBS-C), <3 stools/week and  
(iii) Indeterminate (IBS-I), stool frequency between > 3/week and < 3/day 
 
Positive GHBT 
Positive (or abnormal) GHBT was diagnosed sustained (for at least two consecutive readings) 
rise of breath hydrogen by 20 ppm above basal level (if basal level was <10 ppm) or by 12 
ppm above basal level (if basal level was >10 ppm). Positive GHBT was used as a surrogate 
marker of SIBO in the present study. 
 
OCTT  
Time interval between lactulose administration and sustained (for at least two consecutive 
readings) rise of breath hydrogen by 20 ppm above basal level was considered as OCTT.  If 
there were two peaks, second peak was taken for calculation of OCTT. Measurement of 
OCTT was considered to have failed if they had no peak in breath hydrogen excretion on 
LHBT till end of the test. 
 
Statistical methods 
The data of the present study were recorded manually into the computer and after its proper 
validation, checked for error; coding & decoding were compiled and analyzed using the 
software SPSS 15.0 for windows.  
Quantitative variables were expressed as mean and standard deviation (SD) if normally 
distributed or median and range if not normally distributed, Qualitative variables were 
expressed as proportions.  
 
 Glucose HBT was categorized as positive or negative and numbers of patients in each group 
correlated with additional symptoms of IBS and IBS subgroups. The analysis was done using 
the Chi square test or Fisher’s exact test as applicable. P value of <0.05 was taken as 
significant. 
 
OCTT was expressed as mean and SD in all patients together and in different subgroups of 
IBS. OCTT in different subgroups was analysed using analysis of variance (ANOVA) test. P 
value of <0.05 was taken as significant. 
 
 
  
 
Results 
 
 
 
 
 
 
 
 
 
In the present study total of 194 consecutive patients were recruited from OPD of 
Gastroenterology clinic. Out of these 30 patients were excluded from the study, 26 patients 
did not undergo breath tests despite giving informed consent, 3 patients underwent only 
glucose HBT and did not complete lactulose HBT, and one patient was diagnosed with 
hypothyroidism. After exclusion total of 164 patients were included for final analysis. This is 
presented in study flow chart (Figure 4). 
Figure 4: Flow chart of study 
 
 
 
 
 
 
 
 
Baseline characters of the patients including demographic characters and laboratory data are 
presented in Table no 4.   Mean age of the patients was 39.16 (± 10.36) yrs. Distribution of 
age is depicted in figure no. 5.   Majority of the patients were males comprising 68.9%, 113 
out of 164 of total patients. Sex distribution is presented in figure no 6. Mean BMI of the 
patients was 21.78 (± 3.79) kg/m2.  Hemoglobin concentration was 13.14 (± 1.55) g/dl, with 
average mean corpuscular volume (MCV) of 86.39 (± 8.43) fl. Mean serum albumin level 
was 4.61 (± 0.36) g/dl.  Average fasting blood sugar was 92.53(± 9.73) mg/dl. Mean 
creatinine level was1.05 (± 0.27) mg/dl in study population. 
Total number of patients recruited = 194 
Total number of patients Excluded = 30 
 26 did not undergo HBTs after consent 
                                                                        3 underwent only GHBT 
                                                                 1 diagnosed with hypothyroidism 
Total number of patients included for final analysis = 164 
Table No. 4:  Baseline characters of the patients. Some values shown are actual numbers 
while the others are mean + SD 
Particulars  Total No (n=164) 
Age, years (mean ± SD) 39.16 (± 10.36) 
Sex (Male /Female) 113/51 
Height, cm (mean ± SD) 164.22 (± 7.23) 
Weight, kg (mean ± SD) 59.31 (± 11.41) 
BMI#, kg/m2   (mean ± SD) 21.78 (± 3.79) 
Hemoglobin, g/dl (mean ± SD) 13.14 (± 1.55) 
MCV*, fl (mean ± SD) 86.39 (± 8.43) 
TSH$ , IU/ml (mean ± SD) 2.88 (± 2.02) 
Albumin , g/dl  (mean ± SD) 4.61 (± 0.36) 
Fasting blood sugar, mg/dl (mean ± SD) 92.53 (± 9.73) 
Creatinine, mg/dl (mean ± SD) 1.05 (± 0.27) 
#BMI – Body mass index, *MCV – Mean corpuscular volume,$TSH – Thyroid stimulating hormone 
 
Figure No 5: Distribution of age in study population (n=164) 
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Figure No 6: Distribution of sex in study population (n=164) 
 
Out of total 164 IBS patients, 64 (39.1%) were categorised as diarrhoea predominant (IBS-
D), 24 (14.63%) as IBS –C and 76 (46.34%) were classified as IBS –I.  Subtypes of IBS are 
presented in Figure No 7.  Additional symptoms of bloating were present in 92 (56.1%), 
mucous in stool in 86 (52.4%) and flatulence in 29 (17.7%) of the total number of patients. 
Prevalence of additional symptoms of IBS is presented in Table no. 5.   
 
Figure No 7: IBS subtype distribution (n=164) 
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Table No. 5: Additional symptoms of IBS (n=164) 
Symptom Frequency Percent of total patients 
Bloating 92 56.1% 
Flatulence 29 17.68% 
Mucous in stool 86 52.44% 
 
Baseline characters in different types of IBS are presented in table no.3 and 4.  As can be 
inferred from table no 3, there was statistically significant (p=0.017) difference in sex 
distribution in different subgroups of IBS. Females were present in 45.8% (11), 36.8 % (28) 
and 18.8% (12) in IBS-C, IBS-I and IBS-D subgroups. Additional symptoms of IBS in 
different subgroups are depicted in table no 6. The symptoms of bloating (p=0.5) and 
flatulence (p=0.5) were not statistically different in subgroups of IBS.  Mucous in the stool 
was statistically different in subgroups of IBS with p value of 0.05, with symptom present in 
64.1% (41) in IBS-D, 50 % (12) in IBS –C and 43.4 % (33) in IBS-I. 
 
Table no 6: Distribution of sex in IBS subgroups 
 
IBS subgroup 
Sex  
Total 
 
Male Female P value 
  
IBS-D 
 
(%within IBS subgroup) 
 
 
52 (81.3%) 
 
12 (18.8%) 
 
64 
 
 
 
 
0.017 
 IBS-C 
(%within IBS subgroup) 
13 (54.2%) 11 (45.8%) 24 
 
IBS-I 
(%within IBS subgroup) 
48 (63.2%) 28 (36.8%) 76 
 
 Total 113 (68.9%) 51(31.1%) 164 
 P value as per Pearson’s chi square test 
Table no. 7: Baseline characters in different subgroups of IBS 
IBSTYPE Age 
(years) 
BMI 
(kg/m2) 
HB 
(g/dl) 
MCV  
 (fl) 
Albumin 
(g/dl) 
TSH 
(IU/ml) 
FBS 
(mg/dl) 
Creatinine 
(mg/dl) 
IBS-D           Mean                      
  (n=64)             SD 
38.88
10.62 
21.57 
3.82 
13.36 
1.7 
 
87.09 
8.62 
4.64 
0.45 
2.93 
   1.79 
91.72 
9.38 
  1.11 
0.37 
IBS-C           Mean 
 (n=24)              SD  
40.54 
10.57 
 
20.83 
3.55 
 
12.41 
1.55 
 
87.16 
8.5 
 
4.51 
0.29 
 
3.05 
1.97 
 
90.08 
    10.07 
 1.01 
0.14 
IBS-I             Mean 
 (n=76)            SD 
38.96 
10.167 
 
22.262 
3.8067 
 
13.19 
1.35 
 
85.57 
8.29 
 
4.62 
0.29 
 
2.77 
2.23 
94.00 
9.80 
 
1.02 
0.19 
Total             Mean 
 (n=164)            SD 
39.16 
10.359 
21.784 
3.7886 
13.14 
1.55 
86.39 
8.42 
4.61 
0.36 
2.87 
2.02 
92.53 
9.73 
1.05 
0.27 
 
Table no. 8: Distribution of additional symptoms of IBS in subgroups 
 Bloating Flatulence Mucous in stool 
Yes No Yes No Yes No 
IBS 
TYPE 
IBS-D      33 31 11 
 
53 
 
41 
 
23 
 
IBS-C      15 9 6 
 
18 
 
12 
 
12 
 
IBS-I        44 32 12 
 
64 
 
33 
 
43 
 
Total                       92 
 
72 
 
29 
 
       135 
 
86 
 
78 
 
 
 
P value 
 
0.5 
 
0.5 
 
0.05 
P value as per Pearson’s chi square test 
Glucose HBT was abnormal or positive in 12 patients out of total 164 patients who 
underwent test. Prevalence of abnormal or positive GHBT, which is a surrogate marker of 
SIBO, was 7.32%. Among those who had abnormal GHBT, 7 were in IBS-D subgroup, 4 in 
IBS-I and one in IBS-C subgroup. On subgroup analysis prevalence of abnormal GHBT was 
10.4% (7/64) in IBS-D, 5.3 %( 4/5.3%) and 4.2% (1/24) in IBS-C patients. This data is 
presented in figure no. 8 and table no 9. 
Figure No. 8: Positive glucose hydrogen breath test (GHBT) 
 
 
Table No. 9: Positive glucose hydrogen breath test (GHBT) 
 Positive GHBT Total no of patients Percent prevalence 
All IBS patients 12 164 7.32% 
IBS - D 7 64 10.4% 
IBS - I 4 76 5.3% 
IBS-C 1 24 4.2% 
 
 
Positive GHBT: correlation with sex, age and IBS type 
In order to assess if any predictors can be found for positive GHBT (surrogate marker of 
SIBO) various factors were analyzed.  Positive GHBT was not statistically different in males 
or females (p = 0.518, Fisher’s exact test) which is presented in table no 10. Another 
parameter which was shown to be significantly associated with SIBO, age >55 was assessed.  
As can be seen from table no. 11, age >55 years was not significantly associated with positive 
GHBT (p=0.97, Fisher exact test).  
 
   Table no. 10: Correlation of positive GHBT with sex 
 SEX          p value* 
Male Female 
GLUCOSE 
HBT 
Positive        
 
7 
 
5 
 
 
0.518 Negative       
 
106 
 
46 
       *p value using Fisher’s exact test 
 
 
Glucose 
Hydrogen BT 
 (n =164) 
Positive GHBT 
= 12 (7.32 %) 
IBS – D = 7 
IBS – C = 1 
IBS – I = 4 
  
Table no.11: Correlation of positive GHBT with age 
 Age p value* 
age<55 Age>/=55 
GLUCOSE 
HBT 
Positive       9 3  
0.97 
Negativ
e       
       139 13 
      *p value using Fisher’s exact test 
 
IBS subtype was analyzed to see whether correlation existed with positive GHBT. As can be 
seen from table no. 12, IBS subtype was not statistically associated with positive GHBT 
(p=0.67, Pearson’s chi square test). 
   Table no. 12: Correlation of positive GHBT with IBS subtype 
 IBS subgroup   p value * 
IBS-D IBS-C IBS-I 
GLUCOSE 
HBT 
Positive       6 1 5   0.67 
Negative      58 23 71 
       *p value using Pearson’s chi square test 
 
 
Correlation with additional symptoms of IBS with positive GHBT 
Additional symptoms of bloating, flatulence and mucous in stool were correlated with 
positive glucose HBT to see if any symptom is positively correlated.  Bloating was correlated 
with positive GHBT which was statistically significant with p value of 0.013 using chi square 
test. The other additional symptoms of flatulence and mucous in stool were not statistically 
associated with positive GHBT, with p value of 1.00 and 0.769 respectively. This is depicted 
in table no 13. 
Table no 13. Correlation with additional symptoms of IBS 
  
GLUCOSE HBT 
 
  
Positive Negative p-value 
  
n % n % 
 
Bloating 
Present 11 91.67 81 53.29 
0.013 Absent 1 8.33 71 46.71 
Flatulence 
Present 2 16.67 27 17.76 
   1.00 Absent 10 83.33 125 82.24 
Mucous in 
stool 
Present 7 58.33 79 51.97 
0.769 Absent 5 41.67 73 48.03 
p value with Fisher’s exact test 
 
Orocecal Transit Time (OCTT) 
OCTT was calculated from lactulose hydrogen breath test (LHBT) in the study. Out of total 
164 patients, OCTT could be calculated in 137(83.5%) and incalculable in 27 (16.5%) 
patients. Among 27 patients where OCTT was incalculable, 13 were in IBS-D subgroup 
(13/64, 20.3%), 12 in IBS-I (12/76, 15.8%) and 2 in IBS-C (2/24, 8.3%) subgroups. This is 
depicted in table no. 14. Mean OCTT in all patients where it could be calculable (n=137) 
was114.3 (±25.3) minutes. Mean OCTT in IBS-D, IBS-C and IBS-I was 112.3 (±25.9) min, 
122.8 (±28.3) min and 112.8 (±24.8) min respectively. The data on OCTT is presented in 
figure no. 9. 
 
 
 
Table no 14. Patients with calculable/Incalculable OCTT in subgroups of IBS 
IBS subgroup OCTT calculable OCTT incalculable Total No Percentage  of 
incalculable OCTT 
IBS - D 51 13 64 20.3% 
IBS  - C 22 2 24 8.3% 
IBS - I 64 12 76 15.8% 
Total 137 27 164 16.5% 
 
Figure no. 9: Orocecal Transit Time (OCTT) 
Orocecal Transit Time (OCTT)
Lactulose HBT
OCTT calculable
= 137 (83.5%)
OCTT incalculable
= 27 (16.5%) 
Mean OCTT =
114.3 (±25.3) min
OCTT in IBS-D(n=51)= 112 .3(±25.9) min
OCTT in IBS-C(n=22)= 122.8(±28.3) min
OCTT in IBS-I(n=64)= 112.8 (±24.8) min
 
 
Comparison of OCTT in different subgroups of IBS 
Among the patients in whom OCTT is calculable, it was compared within subgroups of IBS 
to find out if OCTT was different statistically. When analyzed all three subgroups together 
using Analysis of Variaence (ANOVA) test, there was no statistical difference in OCTT 
among these subgroups with p value of 0.255. This is depicted in figure no 10 and table no. 
15. 
Figure no 10: Comparison of OCTT in different subgroups of IBS  
 
Table no 15: Comparison of OCTT in different subgroups of IBS  
*p value as per ANOVA test 
 
The post hoc tests done also reveled there is no difference between the IBS-D and IBS C as 
well as the other combinations.  
 
Correlation of OCTT with positive GHBT 
Mean OCTT in 12 patients of IBS with positive GHBT was 113.75 (±30.31) min and in those 
121 patients with negative GHBT was 114.3 (± 25.34) min. OCTT was not statistically 
different (p=0.94, t test for equality of means) between the two groups. 
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IBS subgroup n Mean Standard Deviation p-value* 
IBS D 51 112.34 25.96  
0.255 
 
IBS C 22 122.86 28.31 
IBS I 64 112.86 24.82 
  
 
 
 
 
 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
IBS is a common functional bowel disease with high prevalence in general population. 
Despite its high prevalence in general populations and the health care costs involved in 
management, the aetiology of IBS is not known exactly. A number of different mechanisms 
have been implicated in the pathogenesis of IBS11,12.  One of the associations of IBS which 
has been proposed is with SIBO and has varied association in various studies done across the 
globe. Few of previous studies have shown that colonic and small bowel transit is prolonged 
in IBS-C and accelerated in IBS-D8. 
 
The present study was planned to find out prevalence of SIBO (as assessed by abnormal 
Glucose HBT) in IBS subjects and also to see whether it correlated with symptoms. Another 
objective of the study was to assess oro-cecal transit time (OCTT) in these subjects (using 
lactulose HBT) and to see if any difference existed in transit time of IBS subgroups. The total 
number of patients included for final analysis of study was 164. 
 
Mean age of the patients in our study was 39.16 (±10.36) years. Age group ranged between 
18-65 years. Among them 24.4% (40) were in age group of 18-30 yrs, 32.3% (53) in 31-40, 
31.1% (51) in 41-50 and 12.2% (20) patients in >50 years. Hence majority of the patients 
were middle aged. In a community based study of IBS patients by Shah et al the mean age 
was 37.2 years6.  In a prospective study by Makharia et al the mean age was 34.6 (± 10.8) 
years25. 
 
In our study majority of patients were males comprising, 68.9% (113) and females comprised 
31.1% (51). This is similar to other hospital based studies from India which evaluated SIBO 
in IBS, 71.1% (160/225) in Rana SV et al17, 69.5% (41/59) by Sachdeva et al19.  But in 
population based studies from India have shown varied sex distribution. In a community 
based study of IBS by Shah et al showed slight male predominance with 56% (1441/2549). In 
study by Makharia et al, prevalence of IBS was higher in females when compared with males 
4.8% vs 3.2%25. Studies from the west have always shown IBS being female predominant 
disease both in hospital and community based studies with Male to female ratio being 1:2 8,15.  
 
Baseline characters of the study are presented in table no. 4 including routine investigations. 
As can be viewed from the table most of the reports are within normal ranges implying that 
patients did not suffer from organic diseases. 
 
In our study IBS-I was the predominant subgroup with 46.3% (76) followed by IBS-D in 
39.1% (64) and IBS-C in 14.6% (24). Males and females were significantly different in these 
subgroups of IBS with p value of 0.017 (table no 6). Females comprised 45.8% (11/24), 
36.8% (28/76) and 18.8% (12/64) in IBS –C, IBS-I and IBS-D respectively. Baseline 
characters were almost similar in different subgroups of IBS (table no. 7). In study by 
Makharia et al 4767 IBS (as per Rome III) subjects from rural north India, included 
subgroups of IBS as -  IBS-M in 42.4%, IBS-D 37.7%, IBS-U 13.6% and IBS-C in 6.3%.  As 
compared with this population based study, our study also showed indeterminate or mixed 
was most common and constipation predominant was least common.  
 
Additional symptoms of bloating, flatulence and mucous in stool were present in 56.1% (92), 
17.68% (29) and 52.44% (86) respectively among total of 164 patients. Bloating and 
flatulence were similar in different subgroups of IBS (p value of 0.5 each, table no. 8). But 
additional symptom of mucous in stool was significantly different in these subgroups of IBS 
with p value of 0.05. 
 
In the present study Positive (or abnormal) GHBT was noted in 7.32% (12/164). This test is 
used as a surrogate marker of SIBO in the present study. Hence prevalence of SIBO in the 
study was 7.32%.  Among these 12 patients with positive GHBT, 7 (10.4%) were in IBS-D, 4 
(5.3%) in IBS-I and 1 (4.2%) in IBS-C.  
 
In a study of 202 (as per Rome I) IBS patients by Pimentel et al using LHBT results 
suggesting SIBO was found in 157 (78%) of patients. LHBT was done with 10 g of lactulose 
and positive HBT taken as >20 ppm above baseline15. In another study by the same group 
with same study design, abnormal LHBT was present in 84% (93/111) vs 20% (3/15) in the 
subjects with IBS and healthy subjects respectively16. In a study from Italy, positive GHBT 
was found in 31% (65) of IBS (as per Rome II),  patients as compared  to 4% (102) in the 
control group which was significant difference51. In this study glucose HBT was done with 
50 g and positive HBT taken as >10 ppm above baseline. A study by Rana SV et al. from 
PGI, Chandigarh showed that the prevalence of SIBO was 11.1% (225) in IBS subjects as 
compared to 1% in controls (100). The study used GHBT (50 gm glucose) to diagnosed 
SIBO, and positive HBT was taken as >12 ppm above baseline17. Prevalence of SIBO in IBS 
(Manning criteria) was 8.5%. in a study by Ghoshal UC. In this study rise in H2 above 12 
ppm from baseline after 100 g glucose was taken as positive for SIBO18. SIBO (i.e. positive 
GHBT) in patients with IBS (Rome III) was 23.7% (14/59) in study by Sachdeva et al. Both 
last two studies used rise in H2 above 12 ppm from baseline after 100 g glucose was taken as 
positive for SIBO18. 
 
Our study showed the lowest prevalence of SIBO (positive GHBT) including other studies 
from north India. Possible reasons for low incidence include 
(a) We did not analyze methane in the study which might have led to under estimation of 
positive GHBT in those who are predominant methane and hydrogen non producers 
(b) Use of stringent criteria for positive (or abnormal) GHBT. In our study Positive (or 
abnormal) GHBT was diagnosed sustained (for at least 2 consecutive readings) rise of breath 
hydrogen by 20 ppm above basal level (if basal level was <10 ppm) or by 12 ppm above 
basal level (if basal level was >10 ppm). We postponed the HBT if baseline breath hydrogen 
was high. 
 
Other possible reasons of variation in dose of glucose used, we used 70 gram, dose of which 
varied in different studies.  
We analysed the different factors to see if any correlation existed with positive GHBT. 
Additional symptom of bloating was correlated with positive GHBT with statistical 
significance (p value 0.013, Fisher’s exact test). Additional symptoms of flatulence (p=1.0), 
mucous in stool (p=0.76), IBS subtype (p=0.67), sex (p=0.518) and age >55 (p=0.97) did not 
correlative significantly with positive GHBT. In a retrospective study Reddymasu  et al,  
which included 98 IBS patients (Rome II) with predominant symptoms of bloating & 
flatulence, showed that older age (more than 55 yr) and female gender were predictors of 
SIBO in subjects with IBS58. A study by Sachdeva et al concluded that IBS-D subgroup, 
female sex and bloating as possible predictors 19.  A study by Law et al concluded that PPI 
therapy did not affect H2 production on LHBT in patients with IBS 59.  
 
With this we can postulate that if IBS patients with bloating undergo GHBT, it is likely SIBO 
may be diagnosed more frequently. Path physiologically bacterial overgrowth in small bowel 
by gas forming organisms can lead to excessive gaseous distension of abdomen which could 
explain symptom of bloating in such patients.  
 
In the present study OCTT was calculated from lactulose hydrogen breath test (LHBT). Out 
of total 164 patients, OCTT could be calculated in 137(83.5%) and incalculable in 27 
(16.5%) patients. OCTT was called incalculable if there was no rise in breath hydrogen level 
till the end of LHBT i.e. 180 min. Mean OCTT in all patients where it could be calculable 
(n=137) was114.3 (±25.3) minutes. Mean OCTT in IBS-D, IBS-C and IBS-I was 112.3 
(±25.9) min, 122.8 (±28.3) min and 112.8 (±24.8) min respectively. Two previous studies 
have shown that OCTT in healthy population is between 40 and 170 min for a liquid meal 
containing lactulose 60 and between 192 - 232 min for a solid meal61 
 
The study showed that OCTT was incalculable in 27 (16.5%) patients. It is possible that these 
patients are hydrogen non producers and predominant methane producers instead. 
Approximately 15% of the healthy subjects are considered as predominant methane 
producers. These indivisual’s intestines are colonized with Methanobrevibacter smithii. In 
these persons hydrogen gas produced reacts biochemically with carbon dioxide to produce 
methane. Thus they produce less hydrogen in breath. This may have affected OCTT results of 
ours study. But these patients (where OCTT was incalculable) were present in all subgroups 
of IBS patients, 13 were in IBS-D subgroup (13/64, 20.3%), 12 in IBS-I (12/76, 15.8%) and 2 
in IBS-C (2/24, 8.3%) subgroups. 
 
There was no statistical difference in OCTT among three subgroups of IBS when analyzed 
with ANOVA with p value of 0.255. Post hoc tests also did not show any difference in OCTT 
among two subgroups of IBS together. A study Cann PA et al included 61 patients with  IBS 
and 53 controls. The study concluded that OCTTs were significantly shorter in subgroup of 
subjects with diarrhoea (3.3±0.3 vs 4.2±0.2 h; p=001) and prolonged  in patients whose with 
constipation (5.4±0.3 vs 4.2±0.2 h; p<001) or pain and distension (5.4±0.4 vs 4.2±0.2 h; 
p<001) in comparison with controls62. In a study by Sadik R et al that included 96 IBS 
subjects showed that small intestine and colonic transit was prolonged in IBS-C in 
comparison with IBS-D subgroup63.  Yu et al in a study showed that the mean OCTT was 
prolonged in IBS-C as compared to IBS-D almost 2.2 times 64. 
 
Limitations and strengths of the study 
There were many limitations in our study. Firstly, we did not analyze methane in the breath 
which may have caused underestimated the prevalence of SIBO and affected OCTT result as 
it was incalculable in 16.5%. Secondly, there was no control population for comparison. 
Strengths of our study include good sample size which included all subtypes of IBS and 
stringent criteria used for abnormal GHBT. 
 
  
 
 
 
 
 
 
Summary and Conclusions 
 
 
 
 
 
 
 
 
 
 Ø  IBS-I was the most common and IBS-C the least common subgroup of IBS 
Ø  Males predominated among the all IBS patients, but sex distribution was significantly 
different in subgroups 
Ø  Prevalence of abnormal glucose hydrogen breath test (a surrogate marker of SIBO) 
was 7.32% which is lower than described in studies from North India 
Ø  The symptom of bloating was significantly correlated with positive GHBT 
Ø  IBS subtype, age or sex did not correlate with positive GHBT 
Ø  Orocecal transit time (OCTT) was incalculable in 16.5% which may represent 
hydrogen non producers 
Ø  Mean OCTT was114.3 (±25.3) minutes in those with  calculable OCTT 
Ø  Orocecal transit time was not different in subgroups of IBS  
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY NUMBER: 
PROFORMA FOR BREATH TEST IN IBS 
Name  
Hospital No  
Age  
Sex  
Occupation  
Residence  
 
Telephone Local :                                                  Permanent:  
Smoking :       Yes /No                            If Yes, Details:  
Alcohol    :      Yes/No                             If Yes, Details:  
 
SYMPTOMS/DETAILS: 
Pain Abdomen Yes/No Upper/Lower/Generalized  
Abdominal Discomfort Yes/No   
Duration 12 weeks or more in 
last 12 months 
Yes/No   
Essential Symptoms of pain/discomfort 
Relived by defecation Yes/No  
Associated with change in Stool Frequency Yes/No  
Associated with change in Stool Consistency Yes/No  
Additional Symptoms 
Abnormal stool 
Frequency 
Yes/No <3/wk    :  >3/d    :  None of these  
Abnormal Stool Form Yes/No Hard/Loose  
Abnormal Stool Passage Yes/No Straining/Urgency/Incomplete evacuation  
Passage of Mucous Yes/No   
Bloating or Distension of 
abdomen 
Yes/No   
Others  :       Flatulence Yes/No   
 
 
HT: __________ cms                WT:___________ kg                                  BMI _____________  kg/m2 
 
SIGNS – Any Significant 
   
   
 
LABS AND OTHER INVESTIGATIONS 
BLOOD:  
Hb MCV A/G TSH 
AC Creatinine   
Others    
    
ENDOSCOPY 
 
IMAGING STUDIES 
 
IBS Subtype:   Diarrhoea Predominant      (   ) 
                        Constipation Predominant (   ) 
                        Indeterminate                       (   ) 
 
GLUCOSE HYDROGEN BREATH TEST -      Positive/Negative 
0 MIN 20 40 60 80 100 120 
       
 
LACTULOSE HYDROGEN BREATH TEST       
0 MIN 15 30 45 60 75 90 105 120 135 150 165 180 
             
 
Orocecal Transit Time (OCTT) - Calculable / Incalculable 
 
OCTT - __________________________   min 
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